

HSV-2 gD (910): sc-57860

BACKGROUND

Two serotypes of the herpes simplex virus, HSV-1 (also known as type 1 or oral) and HSV-2 (type 2 or genital), can establish lifelong latent infections within sensory ganglia. Periodically, the virus reactivates and can cause recurrent cold sores, eye and genital infections and encephalitis. The human herpesvirus entry mediator C (HveC), also known as the poliovirus receptor-related protein 1 (PRR1) and as Nectin 1, allows the entry of HSV-1 and HSV-2 into mammalian cells. HveC contains three Ig-like domains in its extracellular portion. The glycoprotein D (gD) binding site is located within the first Ig-like domain (V domain) of HveC. The interaction of virus envelope gD with HveC is an essential step in the process leading to membrane penetration, fusion and cell-cell spread. The fusion event is dependent on the expression of a gD receptor on target cell membranes and does not require the presence of cell-surface glycosaminoglycans. Utilizing more than one cell receptor for entry, gD is also essential for receptor-mediated entry of α herpes viruses and bovine herpes virus type 1 (BHV-1).

REFERENCES

1. Eisenberg, R.J., Ponce de Leon, M. and Cohen, G.H. 1980. Comparative structural analysis of glycoprotein gD of herpes simplex virus types 1 and 2. *J. Virol.* 35: 428-435.
2. Weis, J.H., Enquist, L.W., Salstrom, J.S. and Watson, R.J. 1983. An immunologically active chimaeric protein containing herpes simplex virus type 1 glycoprotein D. *Nature* 302: 72-74.
3. Cohen, G.H., Dietzschold, B., Ponce de Leon, M., Long, D., Golub, E., Varrichio, A., Pereira, L. and Eisenberg, R.J. 1984. Localization and synthesis of an antigenic determinant of herpes simplex virus glycoprotein D that stimulates the production of neutralizing antibody. *J. Virol.* 49: 102-108.
4. Minson, A.C., Hodgman, T.C., Digard, P., Hancock, D.C., Bell, S.E. and Buckmaster, E.A. 1986. An analysis of the biological properties of monoclonal antibodies against glycoprotein D of herpes simplex virus and identification of amino acid substitutions that confer resistance to neutralization. *J. Gen. Virol.* 67: 1001-1013.
5. Slomka, M.J. 1996. Seroepidemiology and control of genital herpes: the value of type specific antibodies to herpes simplex virus. *Commun. Dis. Rep. CDR Rev.* 3: R41-45.
6. Krummenacher, C., Baribaud, I., Ponce de Leon, M., Whitbeck, J.C., Lou, H., Cohen, G.H. and Eisenberg, R.J. 2000. Localization of a binding site for herpes simplex virus glycoprotein D on herpesvirus entry mediator C by using antireceptor monoclonal antibodies. *J. Virol.* 23: 10863-10872.
7. Rauch, D.A., Rodriguez, N. and Roller, R.J. 2000. Mutations in herpes simplex virus glycoprotein D distinguish entry of free virus from cell-cell spread. *J. Virol.* 24: 11437-11446.
8. Browne, H., Bruun, B. and Minson, T. 2001. Plasma membrane requirements for cell fusion induced by herpes simplex virus type 1 glycoproteins gB, gD, gH and gL. *J. Gen. Virol.* 6: 1419-1422.

RESEARCH USE

For research use only, not for use in diagnostic procedures.

SOURCE

HSV-2 gD (910) is a mouse monoclonal antibody raised against purified HSV-2 gD virions.

PRODUCT

Each vial contains 100 μ g IgG₁ in 1.0 ml of PBS with < 0.1% sodium azide and 0.1% gelatin.

APPLICATIONS

HSV-2 gD (910) is recommended for detection of glycoprotein D of herpes simplex virus 2 origin by Western Blotting (starting dilution 1:200, dilution range 1:100-1:1000) and flow cytometry (1 μ g per 1 x 10⁶ cells).

STORAGE

Store at 4° C, ****DO NOT FREEZE****. Stable for one year from the date of shipment. Non-hazardous. No MSDS required.

PROTOCOLS

See our web site at www.scbt.com for detailed protocols and support products.